Des médicaments de premier ordre contre le VIH
Le dolutégravir est un médicament qui révolutionne la prise en charge de l’infection à VIH. Il entre dans la composition des principaux schémas thérapeutiques combinés.
Unitaid and Japan
VIH et co-infections
The untold story of dolutegravir: When climate impact goes hand-in-hand with access to better treatments
Nouveau rapport d’Unitaid : le principal médicament anti-VIH utilisé dans le monde a permis de réduire les émissions mondiales de CO2 de 26 millions de tonnes
Call for Expression of Interest (EOI): Strengthening sustainable regional manufacturing of therapeutics for Maternal health, Malaria and HIV programmatic priorities in Africa
Call for Expression of Interest (EOI)
The aim of this Call for Expressions of Interest (EOI) is to identify potential industry partners that can contribute to enhancing supply resilience and access to medicines[1] for treatment and/or prevention of postpartum hemorrhage, new malaria treatments and therapeutics for HIV and related co-infections, in Africa by strengthening regional manufacturing and developing the broader supply ecosystem.
- Download Expression of Interest (EOI)
- EOIs should be submitted here
- Deadline for Questions: 30 July 2024
- Q&A Response Document Released: 10 August 2024
Closing Date: 15 August 2024 (17:00 CET)
Webinar providing potential applicants with more information on the EOI
Date: 17 July 2024 (14:00 CET)
Join via Zoom: https://unitaid.zoom.us/j/99652508236?pwd=z1S7DquT3qBDg76N5yKL3X0PmgYMPJ.1
[1] Invitro diagnostics (IVDs) are currently not in scope. An EOI for IVD manufacturers was published in November 2023. IVD manufacturers can submit their expression of interest here: Expression of interest: strengthening the regional supply of in vitro diagnostics in LMICs.